GlassScriptPhysician profile
Mitchell Smith Mcmanis
NPI 1295168383
$5,657.36
in general payments reported to CMS, 2019-2025
27 companies · $743 in 2025
The $743 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,345 · 2022: $1,193 · 2023: $1,307 · 2024: $1,070 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $899.07 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $590.24 | 2021-2025 | Verquvo |
| Abbott Laboratories | $520.68 | 2021-2025 | Gallant, Assurity, Merlin@Home |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $476.36 | 2021-2025 | Lifevest |
| Pfizer INC. | $416.58 | 2021-2025 | |
| Novo Nordisk INC | $358.01 | 2021-2025 | Wegovy |
| Amgen INC. | $326.82 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $315.93 | 2021-2025 | Brilinta, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $306.53 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.18 | 2021-2024 | Jardiance |
| Boston Scientific Corporation | $259.40 | 2022-2024 | Bodyguardian |
| Abiomed | $236.57 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $207.88 | 2024-2025 | |
| Esperion Therapeutics, INC. | $63.94 | 2021-2022 | |
| Atricure, INC. | $54.07 | 2024-2025 | Atriclip Laa Exclusion System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.58 | 2024-2025 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $42.81 | 2021-2022 | |
| Scpharmaceuticals INC. | $40.11 | 2025 | |
| Amarin Pharma, INC. | $36.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.44 | 2021-2025 | Camzyos |
| Cardiovascular Systems INC. | $24.50 | 2022 | |
| Avinger INC. | $21.98 | 2021 | |
| Angiodynamics, INC. | $20.67 | 2024 | Auryon Laser System 100-120 Vac |
| Kiniksa Pharmaceuticals, LTD. | $20.22 | 2023 | Arcalyst |
| Vital Connect, INC | $19.35 | 2025 | Vitalpatch Rtm |
| Lexicon Pharmaceuticals, INC. | $19.16 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $17.32 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Mcmanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.